

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/445, 31/495, 31/535 A61K 31/54		A1	(11) International Publication Number: WO 92/20338 (43) International Publication Date: 26 November 1992 (26.11.92)
(21) International Application Number: PCT/US92/02994		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).	
(22) International Filing Date: 10 April 1992 (10.04.92)			
(30) Priority data: 698,426 10 May 1991 (10.05.91) US			
(71) Applicant: MERRELL DOW PHARMACEUTICALS INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventor: McLEES, Byron, D. ; 525 South Burdick Street, Apartment 3605, Kalamazoo, MI 49007 (US).			
(74) Agents: DIXON, J., Michael et al.; Marion Merrell Dow Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).			

(54) Title: METHOD FOR THE TREATMENT OF GLAUCOMA



(57) Abstract

The present invention is directed to the use of a compound of formula (I), in which R₁ and R₂ each independently are represented by hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, hydroxy, SO₃H, SO₂NH₂, or R₁ and R₂ together may form a fused phenyl ring at the 1,2 or 3,4 positions, with the proviso that when R₁ and R₂ are identical, they represent hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, or halogen; A and B independently represent oxo, thio, or an imino group having the formula -N(R₆)-, wherein the group R₆ is represented by hydrogen or C₁₋₄ alkyl; R₃ is hydrogen, C₁₋₄ alkyl, or hydroxyethyl; n is represented by an integer from 2-5; and R₄ and R₅ are each represented by methyl or together form a cyclopentane or cyclohexane ring; the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof, in the preparation of a medicament for the treatment of glaucoma.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

METHOD FOR THE TREATMENT OF GLAUCOMA

The present invention is directed to a method for the treatment of glaucoma. Another aspect of this invention is directed to new ophthalmic preparations which are useful in 5 the treatment of glaucoma.

Glaucoma is a disorder in which elevated intraocular pressure damages the optic nerve thereby producing blindness. There are two major types of glaucoma, chronic 10 open-angle and acute narrow-angle.

Intraocular pressure is controlled by the dynamics of aqueous humor. The aqueous humor is derived from blood by a process of secretion and ultrafiltration in the ciliary 15 body. Aqueous humor then passes from the posterior chamber of the eye, through the pupil to fill the anterior chamber, which is the space between the back of the cornea and the plane of the iris and pupil. The aqueous humor is reabsorbed through the trabecular meshwork, located in the 20 angle between the cornea and the iris. The aqueous humor then enters the canal of Schlemm so that it may be drained away from the eye.

In chronic open-angle glaucoma, the most common type, a 25 defect in aqueous humor reabsorption exists at the level of the trabecular meshwork. Intraocular pressure rises above its normal maximum of 21 mm HG due to the presence of excess


-2-

aqueous humor. In acute narrow-angle glaucoma, dilation of the iris leads to the physical blockade of the entrance to the canal of Schlemm and a resulting excess of aqueous humor.

5

In accordance with the present invention, it has been discovered that these types of glaucoma can be treated by the administration of an effective amount one of the following compounds:

10



20 in which R₁ and R₂ each independently are represented by hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, hydroxy, SO₃H, SO₂NH₂, or R₁ and R₂ together may form a fused phenyl ring at the 1,2 or 3,4 positions, with the proviso that when R₁ and R₂ are identical, they represent hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, or halogen; A and B independently represent oxo, thio, or an imino group having the formula -N(R₆)-, wherein the group R₆ is represented by hydrogen or C₁₋₄ alkyl; R₃ is hydrogen, C₁₋₄ alkyl, or hydroxyethyl; n is represented by an integer from 2-5; and R₄ and R₅ are each represented by methyl or together form a cyclopentane or cyclohexane ring; the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof.

35

As used in this application:

- a) The term "C₁₋₄ alkyl" refers to a straight chain or branched alkyl group containing up to 4 carbon atoms. Representative examples of suitable alkyl groups include, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl;
- b) The term "halogen" refers to a fluorine, bromine, chlorine or iodine atom;
- c) The term "C₁₋₄" alkoxy refers to a straight chain or branched alkoxy group containing up to 4 carbon atoms. Representative examples of suitable alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy;
- d) The term "patient" as used herein is taken to mean warm-blooded animals, such as mammals, for example, dogs, rats, mice, cats, guinea pigs, horses, cattle, sheep and primates, including humans, and;
- e) The term "glaucoma" should be construed as referring to either chronic open angle glaucoma or acute narrow angle glaucoma.

The expression "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula I. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di- and tri-carboxylic acids.

-4-

Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, 5 cinnamic, salicyclic, 2-phenoxybenzoic and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid.

Some of the compounds represented by Formula I exist as 10 enantiomers. Any reference in this application to the compounds of Formula I, is meant to encompass a specific enantiomer or a racemic mixture.

Preferred compounds are those in which A and B are oxo, 15 R₁, R₂, and R₃ are hydrogen, n is either 2 or 4 and R₄ and R₅ together form a cyclopentane ring. These compounds are 8-[2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-ethyl]-8-azaspiro[4,5]decane-7,9-dione and 8-[2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]butyl]-8-azaspiro-20 [4,5]decane-7,9-dione.

The compounds of Formula I as well as their methods of preparation are known in the art. For example, see United States Patent No. 4,612,312, which is hereby incorporated 25 by reference. The compounds are also known in the art as serotonin 5HT_{1A} antagonists.

It has been discovered that the compounds of Formula I decrease intraocular pressures and are therefore useful in 30 the treatment of glaucoma. The exact mechanism by which these compounds decrease intraocular pressure is not fully understood. However it has been learned that these compounds produce constriction of the sphincter muscle of the iris. Constriction of this muscle produces miosis (ie. 35 constriction of the pupil). Several other drugs which are

known to be useful in the treatment of glaucoma also produce this effect upon the sphincter muscle of the iris. These drugs include pilocarpine, physostigmine, and echothiphate.

5

In acute narrow angle glaucoma, the iris physically blocks the entrance to the Canal of Schlemm. Contraction of the sphincter muscle of the iris ends this physical blockade and allows the outflow of aqueous humor from the 10 eye. In chronic open angle glaucoma, there is no direct blockade of the Canal of Schlemm, rather there is a defect in the manner in which the trabeculae meshwork reabsorbs the aqueous humor. Contraction of the sphincter muscle of the iris improves the reabsorption of aqueous humor through 15 the trabeculae meshwork into the Canal of Schlemm.

If desired, the compounds of Formula I can be administered systemically in order to lower intraocular pressures. They can be administered either orally or 20 parenterally. The quantity of compound required to produce this anti-glaucoma effect will vary widely depending upon the particular compound utilized, the patient, the route of administration, the severity of the patient's glaucoma, the presence of other underlying disease states in the patient, 25 and other medications which are being administered concurrently to the patient. Generally though, if the compounds are being administered systemically, than a patients' glaucoma will respond to a dosage range of from about 0.1 mg/kg/ day to about 100 mg/kg/day. This dosage 30 will typically be administered from 1 to 4 times daily.

The compounds of Formula I can be compounded into a variety of systemic dosage forms, such as for example, tablets, capsules, solutions, elixirs, sterile solutions 35 for injection and sustained release preparations. Methods

-6-


for producing these dosage forms are well known in the art and are disclosed in United States Patent No. 4, 612, 312.

The compounds can also be administered topically via 5 ophthalmic dosage forms such as, for example, ophthalmic drops, ophthalmic ointments, and ophthalmic disks. The ophthalmic drops of the present invention should contain from 0.1-10% w/w of one of the compounds of Formula I. Typically, it will be dissolved in a buffered, isotonic 10 solution containing antimicrobial preservative agents. The ophthalmic ointments will also generally contain from 0.1-10% w/w of one of the compounds of Formula I admixed with a suitable base, such as white petrolatum and mineral oil, along with antimicrobial preservatives. The ophthalmic 15 disks will typically be constructed so as to contain a core of active ingredient surrounded by a polymer matrix such as, for example, a hydrophobic ethylene/vinyl acetate copolymer. Specific methods of compounding these dosage forms, as well as appropriate ophthalmic pharmaceutical 20 carriers are known in the art. REMINGTON PHARMACEUTICALS SCIENCES, 16th Ed. Mack Publishing Co. (1980).

Typically, the ophthalmic drops or ophthalmic ointments will be administered from 1 to 4 times daily. The 25 ophthalmic disks will be administered weekly.

WHAT IS CLAIMED IS:

1. Use of a compound of the formula:



in which R₁ and R₂ each independently are represented by hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, hydroxy, SO₃H, SO₂NH₂, or R₁ and R₂ together may form a fused phenyl ring at the 1,2 or 3,4 positions, with the proviso that when R₁ and R₂ are identical, they represent hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, or halogen; A and B independently represent oxo, thio, or an imino group having the formula -N(R₆)-, wherein the group R₆ is represented by hydrogen or C₁₋₄ alkyl; R₃ is hydrogen, C₁₋₄ alkyl, or hydroxyethyl; n is represented by an integer from 2-5; and R₄ and R₅ are each represented by methyl or together form a cyclopentane or cyclohexane ring; the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof, in the preparation of a medicament for the treatment of glaucoma.

2. Use according to claim 1 wherein said compound is 8-[2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-ethyl]-8-azaspiro[4,5]decane-7,9-dione.

-8-

3. Use according to claim 1 wherein said compound is 8-[2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]butyl 1]-8-azaspiro[4,5]decane-7,9-dione.
4. A pharmaceutical composition suitable for ophthalmic administration comprising an effective amount of a compound of claim 1 in admixture with a suitable ophthalmic carrier.
5. A pharmaceutical composition according to claim 3 wherein said compound is 8-[2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]ethyl]-8-azaspiro[4,5]decane-7,9-dione.
6. A pharmaceutical composition according to claim 3 wherein said compound is 8-[2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]butyl]-8-azaspiro[4,5]decane-7,9-dione.
7. A pharmaceutical composition according to claim 4 wherein said composition is ophthalmic drops.
8. A pharmaceutical composition according to claim 4 wherein said composition is an ophthalmic ointment.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/02994

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 A61K31/445; A61K31/495; A61K31/535; A61K31/54

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
Int.Cl. 5	A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 170 213 (MERRELL DOW) 5 February 1986 cited in the application & US,A,4 612 312 16 September 1986 see abstract; claims ----	1-8
A	EUROPEAN JOURNAL OF PHARMACOLOGY vol. 191, no. 3, 4 December 1990, pages 391 - 400; S.E. GARTSIDE ET AL.: 'EFFECTS OF MDL 73005EF ON CENTRAL PRE- AND POSTSYNAPTIC 5-HT1A RECEPTOR FUNCTION IN THE RAT IN VIVO' see the whole document ----	1-2,4-5

¹⁰ Special categories of cited documents :¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

- "y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

1 03 SEPTEMBER 1992


Date of Mailing of this International Search Report

21.09.92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Office



III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category	Citation of Document, with indication, where appropriate, of the relevant passages	
A	JOURNAL OF MEDICINAL CHEMISTRY vol. 31, 1988, pages 1087 - 1093; M.F. HIBERT ET AL.: 'GRAPHICS COMPUTER-AIDED RECEPTOR MAPPING AS A PREDICTIVE TOOL FOR DRUG DESIGN: DEVELOPMENT OF POTENT, SELECTIVE, AND STEREOSPECIFIC LIGANDS FOR THE 5-HT1A RECEPTOR' see the whole document ----	1, 3-4, 6
A	CHEMICAL ABSTRACTS, vol. 109, 1988, Columbus, Ohio, US; abstract no. 31918D, MIR A.K. ET AL.: 'MDL 72832: A POTENT AND STEREOSELECTIVE LIGAND AT CENTRAL AND PERIPHERAL 5-HT1A RECEPTORS' page 51 ; see abstract ----	1, 3-4, 6
A	CURRENT EYE RESEARCH vol. 6, no. 3, 1987, pages 527 - 532; P. MALLORGA ET AL.: 'CHARACTERIZATION OF SEROTONIN RECEPTOR IN THE IRIS + CILIARY BODY OF THE ALBINO RABBIT' see the whole document ----	1-8
A	EXP. EYE RES. vol. 44, no. 6, 1987, pages 731 - 746; N.N. OSBORNE ET AL.: 'SEROTONIN-ACCUMULATING CELLS IN THE IRIS-CILIARY BODY AND CORNEA OF VARIOUS SPECIES' see page 744 ----	1-8
A	EXP. EYE RES. vol. 45, 1987, pages 721 - 729; K. KROOLITA ET AL.: 'EFFECT OF ALPHA-ADRENERGIC AND SEROTONIN BLOCKERS ON THE ACUTE IRRITATIVE RESPONSE IN THE RABBIT EYE' see the whole document ----	1-8
A	EP,A,0 329 903 (MERRELL DOW) 30 August 1989 see the whole document, esp. page 4, line 58- page 5, line 1 ----	1-8

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9202994
SA 60506

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 03/09/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0170213	05-02-86	AU-B-	578962	10-11-88
		AU-A-	4535385	06-02-86
		CA-A-	1244418	08-11-88
		JP-A-	61246180	01-11-86
		US-A-	4612312	16-09-86
US-A-4612312	16-09-86	AU-B-	578962	10-11-88
		AU-A-	4535385	06-02-86
		CA-A-	1244418	08-11-88
		EP-A, B	0170213	05-02-86
		JP-A-	61246180	01-11-86
EP-A-0329903	30-08-89	AU-A-	3021489	24-08-89
		EP-A-	0329932	30-08-89
		JP-A-	2288880	28-11-90
		US-A-	5011846	30-04-91